Document:

Exhibit 10.5

 

PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT

 

THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT,
dated as of January [•], 2021 (as it may from time to time be amended, this “Agreement”), is entered
into by and between Growth Capital Acquisition Corp., a Delaware corporation (the “Company”) and ___________
(the “Purchaser”).

 

WHEREAS:

 

The Company intends to consummate an initial
public offering of the Company’s units (the “Public Offering”), each unit consisting of one share of Class A
common stock of the Company, par value $0.0001 per share (each, a “Class A Share”), and one-half of one redeemable
warrant;

 

Each whole warrant entitles the holder to
purchase one Share at an exercise price of $11.50 per Share; and

 

The Purchaser has agreed to purchase an aggregate
of 1,393,333 warrants (or 1,533,333 warrants if the over-allotment option is exercised in full) at a price of ________ per warrant
(the “Private Placement Warrants”), each Private Placement Warrant entitling the holder to purchase one Share
at an exercise price of $11.50 per Share.

 

NOW THEREFORE, in consideration of the mutual
promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows:

 

AGREEMENT

 

Section 1.  Authorization, Purchase and Sale; Terms
of the Private Placement Warrants.

 

A.  Authorization
of the Private Placement Warrants.  The Company has duly authorized the issuance and sale of the Private Placement Warrants
to the Purchaser.

 

B.  Purchase and
Sale of the Private Placement Warrants.

 

(i)                 
Simultaneously with the consummation of the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser
and the Company (the “Initial Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser
shall purchase from the Company, an aggregate of 1,393,333 Private Placement Warrants at a price of ________ per warrant for an
aggregate purchase price of ______ (the “Purchase Price”). Purchaser shall pay the Purchase Price by wire transfer
of immediately available funds to the trust account (the “Trust Account”) maintained by Continental Stock Transfer
 & Trust Company, acting as trustee (”Continental”), at least one (1) business day prior to the closing of
the initial public offering (“IPO Closing”).  On the Initial Closing Date, upon the payment by the Purchaser
of the Purchase Price, the Company shall deliver the Private Placement Warrants purchased on such date duly registered in the Purchaser’s
name in book-entry form. 

 

(ii)               
Simultaneously with the consummation of the closing of the over-allotment option in connection with the Public Offering (the “Over-Allotment
Option”) or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (each such date,
an “Over-Allotment Closing Date,” and each Over-Allotment Closing Date (if any) and the Initial Closing Date
being sometimes referred to herein as a “Closing Date”), Purchaser shall purchase up to an additional 140,000
Private Placement Warrants (the “Additional Warrants”), in the same proportion as the amount of the option that
is so exercised, and simultaneously with such purchase of Additional Warrants, as payment in full for the Additional Warrants being
purchased hereunder, and at least one (1) business day prior to the Over-Allotment Closing Date, Purchaser shall pay ______ per
Additional Warrant, up to an aggregate amount of $_______ (the “Over-Allotment Purchase Price”), by wire transfer
of immediately available funds or by such other method as may be reasonably acceptable to the Company, to the Trust Account. On
the Over-Allotment Closing Date, upon the payment by the Purchaser of the Over-Allotment Purchase Price, the Company, at its option,
shall deliver a certificate evidencing the Additional Warrants purchased on such date duly registered in the Purchaser’s
name to the Purchaser or effect such delivery in book-entry form. 

 

     

     

    

 

C.  Terms of the
Private Placement Warrants.

 

(i)  Each Private Placement Warrant
shall have the terms set forth in a Warrant Agreement to be entered into by the Company and Continental in connection with the
Public Offering (the “Warrant Agreement”). Such terms include the fact that the Private Placement Warrants shall
not be transferable, assignable or salable until 30 days after the completion of an initial business combination, subject to certain
exceptions set forth in the Warrant Agreement.

 

(ii)  On or prior to the Effective
Date, the Company and the Purchaser shall enter into a registration rights agreement (the “Registration Rights Agreement”)
pursuant to which the Company will grant certain registration rights to the Purchaser relating to the Private Placement Warrants
and the Class A Shares underlying the Private Placement Warrants.

  

Section 2.  Representations and Warranties of the
Company.  As a material inducement to the Purchaser to enter into this Agreement and purchase the Private Placement Warrants,
the Company hereby represents and warrants to the Purchaser (which representations and warranties shall survive the Closing Date)
that:

 

A.  Incorporation
and Corporate Power.  The Company is a corporation duly incorporated, validly existing and in good standing under the
laws of the State of Delaware and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably
be expected to have a material adverse effect on the financial condition, operating results or assets of the Company.  The
Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement
and the Warrant Agreement.

 

B.  Authorization;
No Breach.

 

(i)  The execution, delivery and performance
of this Agreement and the Warrant Agreement have been duly authorized by the Company as of the Closing Date.  This Agreement
constitutes the valid and binding obligation of the Company, enforceable in accordance with its terms.  Upon issuance in accordance
with, and payment pursuant to, the terms of the Warrant Agreement and this Agreement, the Private Placement Warrants will constitute
valid and binding obligations of the Company, enforceable in accordance with their terms.

 

(ii)  The execution and delivery by
the Company of this Agreement and the Warrant Agreement, the issuance and sale of the Private Placement Warrants, the issuance
of the Class A Shares upon exercise of the Private Placement Warrants and the fulfillment, of and compliance with, the respective
terms hereof and thereof by the Company, do not and will not as of the Closing Date (a) conflict with or result in a breach
of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security
interest, charge or encumbrance upon the Company’s share capital or assets under, (d) result in a violation of, or (e) require
any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative
or governmental body or agency pursuant to the amended and restated certificate of incorporation of the Company (in effect on the
date hereof or as may be amended prior to completion of the contemplated Public Offering), or any material law, statute, rule or
regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject, except
for any filings required after the date hereof under federal or state securities laws.

 

C.  Title to Securities. 
Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Warrant Agreement, the Class A Shares issuable
upon exercise of the Private Placement Warrants will be duly and validly issued as fully paid and nonassessable. On the date of
issuance of the Private Placement Warrants, the Class A Shares issuable upon exercise of the Private Placement Warrants shall have
been reserved for issuance. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement,
the Purchaser will have good title to the Private Placement Warrants and the Class A Shares issuable upon exercise of such Private
Placement Warrants, free and clear of all liens, claims and encumbrances of any kind, other than (i) transfer restrictions
hereunder and under the other agreements contemplated hereby, (ii) transfer restrictions under federal and state securities
laws, and (iii) liens, claims or encumbrances imposed due to the actions of the Purchaser.

 

     

     

    

 

D. Valid Issuance.
The total number of shares of all classes of capital stock which the Company has authority to issue is 110,000,000 shares of common
stock, including 100,000,000 Class A Shares and 10,000,000 shares of Class B common stock, $0.0001 par value per share (“Class
B Common Stock”), and 1,000,000 shares of preferred stock, $0.0001 par value per share (“Preferred Stock”).
As of the date hereof, the Company has issued and outstanding 4,312,500 shares of Class B Common Stock (of which up to 562,500
shares are subject to forfeiture as described in the Registration Statement), no Class A Shares and no shares of Preferred Stock.
All of the issued shares of capital stock of the Company have been duly authorized, validly issued, and are fully paid and non-assessable.

 

E.  Governmental
Consents.  No permit, consent, approval or authorization of, or declaration to or filing with, any governmental authority
is required in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by
the Company of any other transactions contemplated hereby.

 

Section 3.  Representations and Warranties of the
Purchaser.  As a material inducement to the Company to enter into this Agreement and issue and sell the Private Placement
Warrants to the Purchaser, the Purchaser hereby represents and warrants to the Company (which representations and warranties shall
survive the Closing Date) that:

 

A.  Organization
and Requisite Authority.  The Purchaser possesses all requisite power and authority necessary to carry out the transactions
contemplated by this Agreement.

 

B.  Authorization;
No Breach.

 

(i)  This Agreement constitutes a valid
and binding obligation of the Purchaser, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights
and to general equitable principles (whether considered in a proceeding in equity or law).

 

(ii)  The execution and delivery by
the Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by the Purchaser does not and shall
not as of the Closing Date conflict with or result in a breach by the Purchaser of the terms, conditions or provisions of any agreement,
instrument, order, judgment or decree to which the Purchaser is subject.

 

C.  Investment Representations.

 

(i)  The Purchaser is acquiring the
Private Placement Warrants and, upon exercise of the Private Placement Warrants, the Class A Shares issuable upon such exercise
(collectively, the “Securities”), for the Purchaser’s own account, for investment purposes only and not
with a view towards, or for resale in connection with, any public sale or distribution thereof.

 

(ii)  The Purchaser is an “accredited
investor” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of 1933, as amended
(the “Securities Act”).

 

(iii)  The Purchaser understands that
the Securities are being offered and will be sold to it in reliance on specific exemptions from the registration requirements of
the United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s
compliance with, the representations and warranties of the Purchaser set forth herein in order to determine the availability of
such exemptions and the eligibility of the Purchaser to acquire such Securities.

 

(iv)  The Purchaser did not enter into
this Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502(c) under
the Securities Act.

 

     

     

    

 

(v)  The Purchaser has been furnished
with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale
of the Securities which have been requested by the Purchaser.  The Purchaser has been afforded the opportunity to ask questions
of the executive officers and directors of the Company.  The Purchaser understands that its investment in the Securities involves
a high degree of risk and it has sought such accounting, legal and tax advice as it has considered necessary to make an informed
investment decision with respect to the acquisition of the Securities.

 

(vi)  The Purchaser understands that
no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation
or endorsement of the Securities or the fairness or suitability of the investment in the Securities by the Purchaser nor have such
authorities passed upon or endorsed the merits of the offering of the Securities.

 

(vii)  The Purchaser understands that:
(a) the Securities have not been and are not being registered under the Securities Act or any state securities laws, and may
not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold in reliance
on an exemption therefrom; and (b) except as specifically set forth in the Registration Rights Agreement, neither the Company
nor any other person is under any obligation to register the Securities under the Securities Act or any state securities laws or
to comply with the terms and conditions of any exemption thereunder.  The Private Placement Warrants will bear a legend and
appropriate “stop transfer” instructions (or an appropriate notation if the warrants are issued in book entry form)
relating to the foregoing. The Purchaser further understands that the Securities and Exchange Commission (the “SEC”)
has taken the position that promoters or affiliates of a blank check company and their transferees, both before and after an initial
business combination, are deemed to be “underwriters” under the Securities Act when reselling the securities of a blank
check company.  Based on that position, Rule 144 adopted pursuant to the Securities Act would not be available for resale
transactions of the Securities until the one-year anniversary following consummation of an initial business combination despite
technical compliance with the requirements of such Rule.

 

(viii)  The Purchaser has such knowledge
and experience in financial and business matters, knows of the high degree of risk associated with investments in the securities
of companies in the development stage such as the Company, is capable of evaluating the merits and risks of an investment in the
Securities and is able to bear the economic risk of an investment in the Securities in the amount contemplated hereunder for an
indefinite period of time.  The Purchaser has adequate means of providing for its current financial needs and contingencies
and will have no current or anticipated future needs for liquidity which would be jeopardized by the investment in the Securities. 
The Purchaser can afford a complete loss of its investment in the Securities.

 

Section 4.  Conditions of the Purchaser’s
Obligations.  The obligations of the Purchaser to purchase and pay for the Private Placement Warrants are subject to the
fulfillment, on or before the Closing Date, of each of the following conditions:

 

A.  Representations
and Warranties.  The representations and warranties of the Company contained in Section 2 shall be true and correct
at and as of such Closing Date as though then made.

 

B.  Performance. 
The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that
are required to be performed or complied with by it on or before such Closing Date.

 

C.  No Injunction. 
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement
or the Warrant Agreement.

 

D.  Warrant Agreement.  The Company shall
have entered into the Warrant Agreement.

 

Section 5.  Conditions of the Company’s Obligations. 
The obligations of the Company to the Purchaser under this Agreement are subject to the fulfillment, on or before the Closing Date,
of each of the following conditions:

 

     

     

    

 

A.  Representations
and Warranties.  The representations and warranties of the Purchaser contained in Section 3 shall be true and correct
at and as of such Closing Date as though then made.

 

B.  Performance. 
The Purchaser shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that
are required to be performed or complied with by the Purchaser on or before such Closing Date.

 

C.  No Injunction. 
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement
or the Warrant Agreement.

 

D.  Warrant Agreement. 
The Company shall have entered into the Warrant Agreement.

 

Section 6.  Termination.  This Agreement
may be terminated at any time after June 30, 2021 upon the election by either the Company or the Purchaser solely as to itself
upon written notice to the other party if the closing of the Public Offering does not occur prior to such date.

 

Section 7.  Survival of Representations and Warranties. 
All of the representations and warranties contained herein shall survive the Closing Date.

 

Section 8.  Definitions.  Terms used but
not otherwise defined in this Agreement shall have the meaning assigned to such terms in the Registration Statement.

  

Section 9.  Miscellaneous.

 

A.  Successors and
Assigns.  Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or
on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether
so expressed or not.  Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this Agreement
without the prior written consent of the other party hereto, other than assignments by the Purchaser to affiliates thereof.

 

B.  Severability. 
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be
ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

C.  Counterparts. 
This Agreement may be executed simultaneously in two or more counterparts, none of which need contain the signatures of more than
one party, but all such counterparts taken together shall constitute one and the same agreement.

 

D.  Descriptive
Headings; Interpretation.  The descriptive headings of this Agreement are inserted for convenience only and do not constitute
a substantive part of this Agreement.  The use of the word “including” in this Agreement shall be by way
of example rather than by limitation.

 

E.  Governing Law. 
This Agreement shall be deemed to be a contract made under the laws of the State of New York and for all purposes shall be construed
in accordance with the internal laws of the State of New York, without regard to the conflicts of laws principles thereof.

 

F.  Amendments. 
This Agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by
all parties hereto.

 

[Signature page follows]

     

     

    

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement to be effective as of the date first set forth above.

 

	 	
        GROWTH CAPITAL ACQUISITION CORP.

	 	 	 
	 	By:	 
	 	 	Name:  George Syllantavos
	 	 	Title:    Co-Chief Executive Officer

 

 

	 	[                                  ]
	 	 	 
	 	By:	                            
	 	 	Name: 
	 	 	Title:   

 

 

[Signature page to Private Placement
Warrants Purchase Agreement]Exhibit 10.1 

 

CERTAIN IDENTIFIED INFORMATION,
MARKED BY [***], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE
HARM TO THE COMPANY, IF PUBLICLY DISCLOSED.

 

 

 

 

MASTER
SERVICE AGREEMENT

 

This MASTER SERVICE AGREEMENT
(this “Agreement”) is made and entered into as of January 8, 2021 (the “Effective Date”) by and between
Humanigen, Inc., a Delaware corporation (“Client”), and EVERSANA Life Science Services, LLC, and its affiliates, a
Wisconsin limited liability company (“EVERSANA”). Client and EVERSANA may each be referred to herein as a “party”
or collectively as the “parties”.

 

RECITALS

 

A.       Client
is a clinical stage biopharmaceutical company, developing an COVID-19, immunology, immuno-oncology portfolio of monoclonal antibodies.

 

B.       EVERSANA,
either directly or through subcontractors, is in the business of furnishing services including, but not limited to patient services,
compliance services, product channel distribution, professional services, marketing and market access services, data and analytics,
HEOR/RWE and field solution services (“Services”).

 

C.       Client
desires to have EVERSANA furnish certain Services described in this Agreement, and EVERSANA desires to perform such Services upon
the terms and conditions set forth in this Agreement.

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the recitals, mutual covenants and conditions herein contained and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows.

 

		1.	DEFINITIONS. For purposes of this Agreement, the following words shall have
the meanings set forth below:

		A.	“Change in Control” means the occurrence, in a single transaction
or in a series of related transactions, of any one or more of the following events: (a) a sale or other disposition of all or substantially
all of the assets of a party to another person or entity (such person or entity, an “acquirer”); (b) a merger or consolidation
between a party and an acquirer in which the party is not the surviving entity, and in which the stockholders of a party immediately
prior to such transaction own, immediately after the transaction, less than fifty percent (50%) of the voting power of the surviving
entity or its parent; (c) a reverse merger between a party and an acquirer in which the party is the surviving entity and the stockholders
of the party immediately prior to such reverse merger own less than fifty percent (50%) of the voting power of the party or its
parent immediately after the transaction; or (d) an acquisition by any acquirer or “group” within the meaning of Section
13(d) or 14(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the regulations promulgated
thereunder, or any comparable successor provisions (excluding any employee benefit plan, or related trust, sponsored or maintained
by the party or subsidiary of the party or other entity controlled by the party) of the beneficial ownership (within the meaning
of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the party representing at least
fifty percent (50%) of the combined voting
power entitled to vote generally in the election of directors or managers, as applicable, of such party, excluding in any case
issuances of securities by the party in transactions the primary purpose of which is to raise capital for the party.

 

    			Page 1 of 23 

    	 

    

  

 

 

 

		B.	“PHI” means Protected Health Information and “e-PHI”
means Electronic Protected Health Information.

		C.	“Products” means all of the biologic products manufactured, distributed,
or marketed by Client which Client distributes or desires to distribute.

		D.	“Work Product” means all inventions, products, designs, drawings,
notes, documents, data, user statistics, analysis, information, documentation, works of authorship, processes, techniques, know-how,
algorithms, specifications, biological or chemical specimens or samples, hardware, circuits, computer programs, databases, user
interfaces, encoding techniques, and other materials of any kind that EVERSANA may make, conceive, develop or reduce to practice,
alone or jointly with others, as a direct result of performing the Services, or that are specifically related to such Services,
whether or not they are eligible for patent, copyright, mask work, trade secret, trademark or other legal protection.

 

GENERAL
TERMS AND CONDITIONS

 

		1.	SERVICES.

 

Available Services and
additional terms and conditions applicable to each such Service are outlined in the Exhibits to this Agreement. Statement(s) of
Work and/or Exhibits (“SOW”) will set forth the Services to be provided by EVERSANA to Client and the fees to be paid
by Client to EVERSANA in connection therewith.

 

		2.	FEES.

 

2.1       Fees
and Expenses. As compensation for EVERSANA’s performance of the Services, Client shall pay fees and expenses (“Fees”)
in accordance with the applicable SOW, including any initial one-time set- up fee as described in the applicable SOW. Client shall
reimburse EVERSANA for reasonable and properly documented out-of-pocket expenses necessarily incurred in performing Services under
this Agreement as the same shall be set forth in a SOW.

 

2.2       Fee
Increases. On each twelve-month anniversary of the Effective Date, EVERSANA shall have the right to unilaterally increase any
then-current transaction or monthly fees for the Services provided under a SOW by [***] percent ([***]%).

 

2.3       Invoices.
On a monthly basis, or as may be otherwise set forth in a SOW, EVERSANA shall submit an invoice setting forth the Services performed,
time expended and expenses incurred during the applicable period with respect to each active SOW. Client agrees to pay EVERSANA
within [***] days of receipt of each monthly invoice, or as otherwise set forth in a SOW, and agrees EVERSANA may charge
Client a one-and-one-half percent (1.5%) per month service charge, or the maximum rate allowed by law, whichever is less, on all
undisputed invoices that are not paid within [***] days of receipt. Notwithstanding the foregoing, pass through expenses
incurred pursuant to a SOW will be billed as incurred. The Fees accrued during the period between the Effective Date and March
31, 2021 shall be deferred (the "Deferred Fees"). Upon the U.S. Food and Drug Administration’s approval of an Emergency
Use Authorization (“EUA”) for Client’s COVID-19 Product, EVERSANA will invoice Client for the Deferred Fees (the
“Initial Invoice”).

 

    			Page 2 of 23 

    	 

    

  

 

 

 

2.4       Disputed
Fees. Notwithstanding the foregoing, if Client disputes any charges or amounts on any invoice, and such dispute cannot be resolved
promptly through good faith discussions between Client and EVERSANA, then Client will pay the amount of the invoice less the disputed
amount, provided that Client shall diligently proceed to work with EVERSANA to resolve any such disputed amount. Any sums withheld
pursuant to this paragraph shall not accrue service charges, but if the contested invoice is later determined to be valid in amount,
Client shall pay the amount withheld.

 

2.5       Effect
of Failure to Pay. In the event that any invoice, other than the amount of any disputed charges or amounts reflected on such
invoice, is not timely paid as provided herein, EVERSANA may, in addition to any other right or remedy that it may have under this
Agreement or at law, suspend Client’s use of any Services provided hereunder or under any SOW if EVERSANA has not received
payment in full within [***] days of EVERSANA’s written demand for payment of the undisputed amount of such invoice.

 

		3.	TERM AND TERMINATION.

 

The initial term of this
Agreement begins on the Effective Date and shall continue for a period of one (1) years (“Initial Term”). After the
Initial Term this Agreement shall automatically renew for successive twelve (12) month periods (“Term”) unless this
Agreement and/or any SOW hereunder is sooner terminated by either party as provided herein or at least [***] days prior to
the end of the then-current renewal period, either party gives the other party written notice of termination. In addition, after
the expiration of the Initial Term, Client shall be permitted to terminate this Agreement and/or any SOW upon at least [***]
days’ prior written notice of termination to EVERSANA.

 

3.1       Termination
for Lack of Approval. Notwithstanding the foregoing, in the event the FDA does not approve an EUA for the Product by April
30, 2021 or such later date as to which the parties otherwise may agree, either party may terminate the Agreement immediately.
In the event of a termination pursuant to this Section 3.1, EVERSANA shall cancel the Initial Invoice and Client shall not be required
to pay any of the Deferred Fees.

 

3.2       Change
in Law. This Agreement may be terminated by either party giving written notice of termination to the other party if there is
any change in the law that makes operation of the Services as contemplated in this Agreement illegal or commercially impractical.

 

3.3       Material
Breach. This Agreement may be terminated by the non-breaching party giving written notice of such termination to the other
party if the other party breaches a material provision of this Agreement and such breach remains uncured for thirty (30) days.

 

3.4       Insolvency.
Immediately upon notification or at any time thereafter, either party may terminate this Agreement in the event that:

 

		(i)	the other party shall file any petition under any bankruptcy, reorganization,
insolvency or moratorium laws, or any other law or laws for the relief of or in relation to the relief of debtors;

		(ii)	there shall be filed against the other party any involuntary petition under
any bankruptcy statute or a receiver or trustee shall be appointed to take possession of all or substantial part of the assets
of the party which has not been dismissed or terminated within ninety

(90) days of the date of such
filing or appointment;

		(iii)	the other party shall make a general assignment for the benefit of creditors
or shall become unable or admit in writing its inability to meet its obligations as they mature; or

		(iv)	the other party shall institute any proceedings for liquidation or the winding
up of its business other than for purposes of reorganization, consolidation or merger.

 

    			Page 3 of 23 

    	 

    

  

 

 

 

3.5       Effect
of Termination. Termination or expiration of this Agreement for any reason provided herein does not relieve either party from
its obligation to perform up to the effective date of such termination or expiration or to perform such obligations as may survive
termination or expiration of this Agreement. If payments attributable to Services performed before the termination or expiration
remain unpaid upon the termination or expiration of the Agreement, Client shall make such payments promptly after the termination
or expiration of this Agreement. In the event of termination, EVERSANA will use reasonable efforts to terminate work being performed
by firms outside of EVERSANA (e.g. subcontracted resources) and other related commitments entered into by EVERSANA but Client will
be responsible for all costs incurred by EVERSANA from such other firms and such other commitments approved by Client that could
not be terminated. Client will be responsible for all EVERSANA time and expenses for Services performed up to date of termination.
Upon the termination or expiration of this Agreement or any SOW, EVERSANA shall provide reasonable transition services, for a period
not to exceed [***] days, as requested by the Client to facilitate the orderly transfer of Services to Client or another services
provider. EVERSANA shall provide the transition services on a time and materials basis at the rates set forth [***].

 

3.6       Survival.
The rights and obligations of the parties under Sections 2, 3.5, 6-9, 12, 14-15, 21-23 and 25 will survive the expiration or termination
of this Agreement.

 

 

		4.	NON-ASSIGNMENT.

 

Neither Client nor EVERSANA
shall assign this Master Services Agreement or any of their rights and obligations under this Master Services Agreement to another
party without the prior written consent of the other party; provided, however, that in the event of a Change in Control (as defined
above), either party may assign its rights and obligations hereunder, by no less than thirty (30) days written notice to the other
party, to a successor or transferee (whether by merger, consolidation, purchase or otherwise) of either all or substantially all
of the assets of such party or any part of the business to which it pertains. This contract will inure for the benefit of and be
binding upon Client and EVERSANA and their respective successors and permitted assigns including, without limitation, any acquirer
of either Client or EVERSANA.

 

		5.	FORCE MAJEURE.

 

Neither party shall be
deemed in default in the performance of its obligations under the Agreement to the extent such performance is temporarily prevented
or delayed because of war, hostilities, riots, acts of terrorism, civil commotion, epidemic, earthquake, accident, fire, wind,
flood, strike or comparable labor shutdowns outside of the reasonable control of the party, or any other act of God; provided
that prompt notice of such Force Majeure shall be given by such party to the other party followed within a reasonable time by
written confirmation. In such event, the noticing party shall be temporarily relieved of its obligations during the period of
such event to the extent such event prevents its performance. If the Force Majeure event continues for one or more related periods
of at least sixty (60) days, the other party shall have the unilateral right to terminate this Agreement by fourteen (14) days
prior written notice. 

 

		6.	CONFIDENTIAL INFORMATION.

 

As used in this
Agreement, the term “Confidential Information” shall mean any and all trade secrets and other confidential
information disclosed by a party or its affiliates, agents, employees and representatives (the “Disclosing
Party”). “Confidential Information” shall include, without limitation, any information concerning the
Disclosing Party’s business plan, processes and methods, product or process specifications and designs, inventions,
technical know-how, trade secrets, business and marketing plans, financial information, customer data, research and
development activities and other materials or information relating to its business or activities which are not generally
known to the public, all confidential information of third-parties in the possession of the Disclosing Party; and all
reports, notes, analyses, compilations, studies, summaries, memoranda and other material prepared by or for the Disclosing
Party containing, reflecting or based, in whole or in part, on any information included in the foregoing. For the avoidance
of doubt, the parties acknowledge and agree that information and data gathered by the parties relating to patients,
including, without limitation, patient numbers, locations and the manner in which Client identified such patients, shall be
Client’s Confidential Information and EVERSANA shall be deemed to be the Receiving Party of such Confidential
Information regardless of the party that discloses the Confidential Information hereunder. The term “Confidential
Information” shall not include any information that is (i) publicly known or becomes publicly known through no breach
of this Agreement by the party receiving or accessing the Confidential Information (the “Receiving Party”) or on
the Receiving Party’s behalf, (ii) rightfully received from a third party without an obligation of confidentiality to
the Disclosing Party with respect to the information received, or (iii) approved by the Disclosing Party for disclosure.

 

    			Page 4 of 23 

    	 

    

 

 

 

 

		7.	NON-DISCLOSURE.

 

During
the Term of this Agreement and for a period of [***] years (or such longer period if required by law) thereafter, the Receiving
Party shall keep the Disclosing Party’s Confidential Information in the strictest confidence (whether such Confidential
Information was disclosed to the Receiving Party before, on or after the Effective Date) and shall not disclose, or permit
the disclosure of, any Confidential Information to any third party without the prior consent of the Disclosing Party. The
Receiving Party shall not use, or permit the use of, any Confidential Information, without the prior consent of the
Disclosing Party, for any purpose other than in connection with the proper performance of the Receiving Party’s
obligations under this Agreement. The Receiving Party shall use its best efforts to prevent any inadvertent disclosure or
unauthorized reproduction or use of the Confidential Information. The Receiving Party shall protect the Disclosing
Party’s Confidential Information with no less than the same degree of care as the Receiving Party would protect its own
Confidential Information, and in any event, no less than a reasonable degree of care. The Receiving Party shall be liable for
breach of its obligations under this Section 7 by its employees and contractors. The Receiving Party will immediately advise
the Disclosing Party in writing if the Receiving Party becomes aware of any misappropriation or misuse by any person of the
Disclosing Party’s Confidential Information. Notwithstanding the foregoing, the Receiving Party may disclose the
Confidential Information of the other party to the extent such Confidential Information is required to be disclosed pursuant
to a requirement of a Regulatory Authority or law, provided that: (a) the Receiving Party has given the Disclosing Party
prior written notice of such disclosure and takes all available steps to maintain the confidentiality of the information
disclosed; and (b) to the extent legally permitted, the Disclosing Party has been afforded a reasonable opportunity to
contest the necessity and scope of such disclosure. The Receiving Party acknowledges and agrees that the Disclosing Party
considers the Confidential Information to be valuable, confidential and a trade secret. Unless otherwise required by law, the
Receiving Party shall, at Disclosing Party’s election, destroy (unless prohibited by applicable law) or promptly return
to the Disclosing Party, in good order, the originals and all copies of Confidential Information, regardless of the medium in
which they are stored, upon the termination or expiration of this Agreement or at any other time upon the reasonable request
of the Disclosing Party except for:

 

		a.	archival electronic information that is electronically archived in the normal course and not
in general use;

		b.	information which must otherwise be maintained as a requirement of law or regulation; and

		c.	one (1) copy of the Confidential Information to the extent reasonable to permit the Receiving
Party to keep evidence that it has performed its obligations under this Agreement

 

provided, in each case of
clause 7(a) to 7(c), that the confidentiality and non-use restrictions set out in clause 7, shall continue to apply to such Confidential
Information, except that the Receiving Party shall not make any further use or disclosure of the Confidential Information.

 

    			Page 5 of 23 

    	 

    

  

 

 

 

		8.	INTELLECTUAL PROPERTY

 

8.1       Client
Property. EVERSANA understands and agrees that all rights to the intellectual property, information and materials of Client
that are provided in connection with this Agreement, including, without limitation, the Products or Client Confidential Information,
are owned solely by Client (“Client Property”). Client hereby grants EVERSANA a non-exclusive, world-wide, non-transferable,
non-sublicensable, royalty-free, fully paid up license to use the Client Property for the purpose of performing the Services hereunder
or pursuant to any SOW, and only for so long as the Services are being performed by EVERSANA pursuant to the applicable SOW. Neither
EVERSANA nor any of EVERSANA’s employees, contractors or agents shall reverse engineer, disassemble or decompile any prototypes,
software, algorithms, or other tangible or intangible objects which are embodied in Client Property or Client’s Confidential
Information and which are made available to EVERSANA and its employees, contractors or agents hereunder. EVERSANA shall not (i)
modify, translate, or otherwise create derivative works based on Client Property, or (ii) use, analyze, transcribe or transmit
any Client Property. EVERSANA shall not remove or alter any proprietary rights notices in or on the original Client Property or
Client’s Confidential Information. EVERSANA shall immediately notify Client in the event of any unauthorized use or disclosure
of Client Property of which EVERSANA becomes aware and shall indemnify Client for any violations of this Section by EVERSANA or
its employees, contractors or agents.

 

8.2       Work
Product. EVERSANA will, as an integral part of the performance of the Services, disclose in writing to Client all Work Product.
Except as expressly set forth herein, any Exhibit attached hereto, or applicable SOW, EVERSANA agrees that all Work Product shall
constitute Client Property and be considered as “works made for hire” under the United States Copyright Laws (17 U.S.C.
§ 101 et seq., and any amendments) or similar law of any other jurisdiction. To the extent that Client does not own full right,
title, and interest in the Work Product under the preceding sentence, EVERSANA hereby irrevocably assigns to Client all of its
right, title, and interest in the Work Product, including all copyrights, patents, trademarks, trade secrets, and other intellectual
property rights (“Intellectual Property”) related to the Work Product. Unless the applicable Exhibit or SOW specifies
a different scope of license for particular EVERSANA Property (as defined below) that is provided on a stand-alone basis during
the term of this Agreement, EVERSANA hereby grants Client a non-exclusive, world-wide, perpetual, royalty-free, fully paid up license
to use, distribute, modify, import, perform, display, reproduce, print, copy and maintain in electronic and hard copy format any
EVERSANA Property contained within any Work Product or otherwise provided to Client under this Agreement for Client’s business
purposes.

 

8.3       EVERSANA
Property. Notwithstanding anything to the contrary contained in this Agreement or any SOW, the following shall not constitute
Client Property (i) any EVERSANA proprietary technology existing prior to the Effective Date or that is developed or acquired by
EVERSANA independent of the Services performed pursuant to this Agreement, including but not limited to, computer consulting knowledge,
techniques, tools, routines and sub-routines, utilities, know-how, portals, methodologies (“EVERSANA Background Technology”)
(ii) any updates, modifications, enhancements, or improvements to EVERSANA Background Technology that are developed by EVERSANA
in the course of performing the Services (“EVERSANA Improvements” and, collectively with EVERSANA Background Technology,
“EVERSANA Property”), and, as between the parties, all EVERSANA Property shall be and remain the sole and exclusive
property of EVERSANA, subject to the license under Section 8.2, (iii) software, including but not limited to any proprietary code
(source and object), which is subject to third-party license agreements, and (iv) those portions of the Work Product that include
information in the public domain or that are generic ideas, concepts, know-how and techniques within the computer design, support
and consulting business generally.

 

    			Page 6 of 23 

    	 

    

  

 

 

 

8.4       Treatment
of EVERSANA Property. Neither Client nor any of Client’s employees, contractors or agents shall reverse engineer, disassemble
or decompile any prototypes, software, algorithms, or other tangible or intangible objects which are embodied in EVERSANA Property
or EVERSANA Confidential Information and which are made available to Client and its employees, contractors or agents hereunder.
Except as expressly set forth under Section 8.2, Client shall not (i) modify, translate, or otherwise create derivative works
based on EVERSANA Property, or (ii) use, analyze, transcribe or transmit any EVERSANA Property. Client shall not use or disclose
any EVERSANA Property either by itself or in coordination with other third parties, to offer or perform services substantially
similar to those offered and/or provided by EVERSANA hereunder, or that are competitive, directly or indirectly, to the business
of EVERSANA. Client shall not remove or alter any proprietary rights notices in or on the original EVERSANA Property or Confidential
Information. Client shall immediately notify EVERSANA in the event of any unauthorized use or disclosure of EVERSANA Property
of which Client becomes aware and shall indemnify EVERSANA for any violations of this Section by Client or its employees, contractors
or agents.

 

8.5       Priority.
To the extent any of the provisions in this Section 8 conflict with those in a specific Exhibit hereto, the provisions of that
Exhibit shall prevail with respect to the Services described in said Exhibit.

 

 

		9.	NON-SOLICITATION.

 

During the Term of this
Agreement and for a period of twelve (12) months thereafter, without the prior written consent of EVERSANA, Client shall not, directly
or indirectly, in any manner solicit or induce for employment, or hire or engage the Services of, any employee of EVERSANA or its
affiliates who performed any work under this Agreement. A general advertisement or notice of a job listing or opening or other
similar general publication of a job search or availability to fill employment positions, including on the internet, shall not
be construed as a solicitation or inducement for the purposes of this provision so long as the circumstances indicate that the
same was not targeted or directed at EVERSANA employees.

 

If Client breaches this
provision, Client shall pay to EVERSANA a sum equal to one year’s base salary that was payable by EVERSANA to that employee,
plus the recruitment costs incurred by EVERSANA in replacing such individual.

 

		10.	GOVERNING LAW; INTERPRETATION.

 

This Agreement shall be governed by and interpreted
in accordance with the internal laws of the State of Delaware, United States of America.

 

		11.	NOTICE.

 

All notices and other communications
that may be or are required to be given hereunder shall be in writing and delivered via electronic mail; shall be deemed to have
been duly given on the date of delivery; and shall be addressed as follows:

 

If to EVERSANA:

General Counsel

EVERSANA Life Science Services, LLC 190 N.
Milwaukee Street

Milwaukee, WI 53202 E-mail: 

 

    			Page 7 of 23 

    	 

    

  

 

 

 

If to Client:

Chief Executive Officer

Humanigen, Inc.

533 Airport Blvd., Suite 400

Burlingame, CA 94010

E-mail: cdurrant@humanigen.com

 

With a copy, which shall not constitute notice hereunder,
to:

 

Chief Commercial Officer Humanigen, Inc.

533 Airport Blvd., Suite 400

Burlingame, CA 94010

E-mail: ejordan@humanigen.com

 

Either party may change
its address for purposes of notice pursuant to this Agreement by notifying the other party of such change of address in the manner
set forth above, except that notices for changes of address are effective only upon receipt by the other party.

 

		12.	ATTORNEYS’ FEES.

 

The prevailing party in
any suit, proceeding or other action brought against the other party to enforce the terms of this Agreement or any rights or obligations
hereunder shall be entitled to receive reimbursement of its reasonable costs, expenses and disbursements (including court costs
and attorneys’ fees) incurred in connection with such enforcement.

 

		13.	INDEPENDENT CONTRACTORS.

 

The relationship of the
parties is that of independent contractors. Neither party has the authority to bind the other, except only to the extent expressly
set forth herein. Nothing herein is intended to create or shall be construed as creating between the parties the relationship of
joint venturers, partners, employer/employee or principal and agent.

 

		14.	INDEMNIFICATION.

 

Each party will
defend, indemnify and hold harmless the other party, its officers, directors, employees, sublicensees, customers and agents
from and against any and all losses, liabilities, damages, expenses and costs (including reasonable attorney’s fees)
(“Losses”), including Losses resulting from third party claims, demands, suits or proceedings, to the extent
arising out of (i) its negligence, intentional misconduct or bad faith, (ii) any breach of its confidentiality obligations
under this Agreement, or (iii) an actual material breach of
this Agreement or any Statement of Work on the part of the indemnifying party. EVERSANA will defend, indemnify and hold
harmless the Client, its officers, directors, employees, sublicensees, customers and agents from and against any and all
Losses resulting from or alleging that any of the Work Product or EVERSANA Property provided by EVERSANA under this Agreement
infringes or misappropriates any third-party’s Intellectual Property. Each party will notify the other party promptly
upon learning of a claim, demand, suit, or proceeding that might give rise to a Loss, and the potentially indemnifying party
may control defense and settlement thereof provided it does so diligently, in good faith, and using reasonably experienced
counsel with expertise in the relevant field. The Indemnified Party shall give the Indemnifying Party timely written notice
and reasonable cooperation and assistance in the defense of any Losses; provided however, that failure of the Indemnified
Party to give such notice shall not limit the Indemnified Party’s right to indemnification except in such case where
such failure was known to the Indemnified Party and materially and adversely affects the Indemnifying Party’s ability
to defend against such Losses. The potentially indemnified party will reasonably cooperate in such defense and/or settlement
at the potentially indemnifying party’s request and expense and may participate at its own expense using its own
counsel. In no event shall the Indemnified Party be liable for any claims that are compromised or settled in violation of
this Section. In the event of a dispute in connection with the validity of this Section (Indemnification), all costs, fees
and expenses, including but not limited to attorneys’ fees, shall be allocated as set forth in Section 12 hereof.

 

    			Page 8 of 23 

    	 

    

  

 

 

 

Client shall reimburse EVERSANA
for all of the out-of-pocket costs and expenses (including, reasonable attorneys’ fees) incurred by EVERSANA in connection
with any of the following events or occurrences, except to the extent that such events or occurrences are caused by gross negligence,
bad faith or reckless or intentional misconduct by EVERSANA or a breach by EVERSANA of its express obligations contained in this
Agreement: (i) any directed inspection, investigation or inquiry by any regulatory authority attributable to Client or its Products
or business practices; or (ii) any court or regulatory authority order, subpoena, interrogatory, demand, request for admission
or other process of law directed to EVERSANA and specifically attributable to Client or its Products or business practices; or
(iii) any request by Client to produce documentation or information, or give testimony or other services in connection with either
(i) or (ii) above.

 

The parties hereto acknowledge
that EVERSANA has not had and will not have any role in the manufacture, labeling, or packaging of Products and that, as between
the parties, Client shall have the sole liability for any product liability or similar claims (regardless of the legal theory upon
which such claims may be brought) with respect to Products.

 

Accordingly, except to the
extent caused by the gross negligence, bad faith or reckless or intentional misconduct by EVERSANA or a breach by EVERSANA of its
express material obligations contained in this Agreement, Client indemnifies and agrees to defend and hold EVERSANA and its members,
directors, officers, managers, employees and agents (“EVERSANA Indemnitees”), harmless from any and all third- party
claims and resulting damages (whether for bodily injury or death, third-party property damage or otherwise), demands, causes of
action, losses, judgments, costs and expenses of any nature whatsoever, including, without limitation, reasonable attorneys’
fees (collectively, “Claims”) to the extent caused by or attributable to:

 

		(i)	Any defect(s) in the manufacture of any Product, inherent safety risks of
any Product or dangerous side effects of any Product;

		(ii)	The manufacturing, labeling, and packaging of any Product;

		(iii)	Marketing practices of Client, off-label usage of any Product or the promotion
of off-label usage, fraud, criminal or civil investigation, inspection or inquiry by or on behalf of any regulatory agency or other
entity in connection with any Product, Client, its business or its representatives;

		(iv)	Any actual or asserted violation of the Federal Food, Drug and Cosmetic Act
or any other Law by virtue of which any Product is alleged or determined to be adulterated, misbranded, mislabeled or otherwise
not in full compliance with such law;

		(v)	Any actual or asserted infringement or violation of any patent, trademark,
trade name, copyright or other intellectual or proprietary rights of any third party with respect to any Product or information
relating to any such Product (excluding the Work Product or other hardware, software, data, or materials provided by EVERSANA under
this Agreement); or

		(vi)	EVERSANA’s use of or reliance upon any information, documents, direction
or instruction provided, supplied or approved by Client or its representatives regarding any Product, Client, or its business.

 

		15.	LIMITATION OF CERTAIN DAMAGES; NO OTHER WARRANTIES.

 

Except in
circumstances of gross negligence, bad faith or reckless or intentional misconduct by a party or its affiliates or
subcontractors, or with respect to a party’s indemnity obligations under this Agreement, a party’s
confidentiality obligations under this Agreement, a party’s violation of law, or third party claims, in no event shall
either party, its affiliates or their respective shareholders, managers, directors, officers, employees and agents be liable
for any indirect, special, exemplary, punitive or consequential damages (including lost profits), whether or not contemplated
or foreseeable, whether a claim is brought at law or in equity and regardless of whether any claim is based upon contract,
tort or other principles.

 

    			Page 9 of 23 

    	 

    

  

 

 

 

Except in
circumstances of negligence, bad faith or reckless or intentional misconduct by a party or its affiliates or subcontractors,
or with respect to a party’s indemnity obligations under this Agreement, a party’s confidentiality obligations
under this Agreement, a party’s violation of law, or third party claims, each party acknowledges and agrees that each
party’s maximum liability to the other party arising out of any claim under this Agreement shall in no event exceed [***] dollars ($[***]) during the twelve (12) months following the Effective Date and [***] dollars
($[***]) thereafter.

 

EVERSANA represents
and warrants to the Client that (i) it will use qualified personnel to perform the Services in a professional and workmanlike
manner consistent with commercially reasonable standards, (ii) it will perform the Services in compliance with all applicable
laws, rules, and regulations, (iii) no Work Product or EVERSANA Property provided by EVERSANA under this Agreement infringes
or misappropriates any third party’s Intellectual Property, and (iv) it has the full power and authority to grant the
Intellectual Property and other rights granted in this Agreement without the further consent of any third party.

 

Except as expressly set
forth in this Agreement, EVERSANA makes no other representations, warranties or promises, express or implied, including any warranty
of merchantability or fitness for a particular purpose.

 

		16.	ENTIRE AGREEMENT.

 

This Agreement, together
with the Exhibits and SOWs attached hereto, contains the entire understanding between the parties and supersedes and cancels any
and all prior agreements, written or oral, between them regarding the within subject matter. There are no representations, agreements,
arrangements or understandings, oral or written, between or among the parties hereto relating to the subject matter of this Agreement
that are not fully expressed herein.

 

		17.	SEVERABILITY.

 

If any provision of this
Agreement is held invalid or unenforceable by a court of competent jurisdiction, the remaining provisions of this Agreement will
remain in full force and effect, and the provision affected will be construed so as to be enforceable to the maximum extent permissible
by law.

 

		18.	WAIVER.

 

The failure by either party to enforce any provision
of this Agreement will not constitute a waiver of future enforcement of that or any other provision.

 

 

		19.	EQUAL OPPORTUNITY EMPLOYER.

 

EVERSANA provides equal
employment opportunities to all employees and applicants for employment without regard to race, color, religion, sex, national
origin, age, handicap, disability, or status as a Vietnam- era or special disabled veteran in accordance with applicable state
or federal laws.

 

		20.	COUNTERPARTS.

 

This Agreement may be signed by the parties
in separate counterparts, which shall together constitute one and the same agreement. Facsimile signatures shall have the same
effect as originals.

 

    			Page 10 of 23 

    	 

    

  

 

 

 

		21.	DISPUTE RESOLUTION.

 

Except to the extent necessary
to prevent irreparable harm or preserve rights or remedies, if any dispute between the parties arises out of or relates to this
Agreement, or the alleged breach thereof, the parties agree to the following mandatory, binding alternative dispute resolution
procedures in lieu of litigation:

 

		(i)	Within five (5) business days of receipt by one party of a written claim
or notice of dispute by the other party, the parties shall commence good faith negotiations to settle the dispute.

		(ii)	If the dispute cannot be settled through negotiation after thirty (30) days, any remaining controversy

or claim shall be settled and
determined by arbitration administered by the American Arbitration

Association under its Commercial
Arbitration Rules. A single arbitrator shall conduct all arbitration proceedings in New York. Subject to reimbursement under the
arbitrator’s final decision as outlined below, the parties shall share equally all costs charged by the American Arbitration
Association and its agents, representatives, employees or independent contractors.

		(iii)	The arbitrator also shall determine which is the prevailing party and shall include in the award
or

relief the reasonable attorney's
fees and costs of such prevailing party in the arbitration. The arbitrator

shall make his or her decision
based upon the applicable legal principles and upon the evidence presented by the parties, and at the request of any party prior
to conclusion of the hearing, shall provide a written reasoned decision which shall include findings of fact and conclusions of
law supporting the decision. This Section does not limit either party’s right to provisional or ancillary remedies from a
court of competent jurisdiction, and the exercise of any such remedy does not waive either party’s right to arbitration.
Judgment on an arbitration award may be entered by any court with competent jurisdiction.

 

		22.	SUB-CONTRACTING.

 

In the event that EVERSANA
contracts with a subcontractor any of its obligations hereunder, Eversana shall (i) remain liable for the performance of such
obligations and will be responsible for the acts and omissions of its subcontractors, (ii) require its permitted
subcontractors to agree in writing to be bound by the obligations of this Agreement, and (iii) remain Client’s sole
point of contact regarding the Services provided hereunder (including any deliverables), including with respect to
payment.

 

		23.	RECORDS AND AUDITS.

 

Each party shall keep full,
complete and accurate records in connection with its provision of the Services and use of the Services during the Term of this
Agreement and for a period of three years thereafter, or for such periods as are required to comply with applicable laws (if longer).
Following conclusion of the Services transfer of such records by EVERSANA to Client shall relieve EVERSANA of any further obligation
under this provision. Each party shall have the right, upon not less than fourteen (14) days advance written notice and during
normal business hours, to inspect or audit, or have inspected or audited at its cost, all such records, including records stored
electronically, for the purpose of verifying fees or compliance with other terms and conditions of this Agreement. Any such inspection
shall not last more than one (1) business day or eight (8) total hours, whichever is less, and audit may not be performed more
often than once in any twelve (12) month period.

 

		24.	AGREEMENT MODIFICATIONS.

 

No modification of this Agreement shall be
effective unless it is in writing and signed by an authorized representative of each party.

 

    			Page 11 of 23 

    	 

    

 

 

 

 

		25.	COMPLIANCE WITH LAW.

 

Both Client and EVERSANA
shall obtain and maintain all applicable material, professional and institutional licenses and certifications required by federal
and state laws and professional boards having jurisdiction over the Services to be provided hereunder. In providing the product
and performing the Services, as applicable, both Client and EVERSANA will comply with all applicable federal, state and local laws,
including without limitation, all applicable regulations and rules relating to Health Insurance Portability and Accountability
Act of 1996 (“HIPAA”), as well as drug manufacturing, pharmacy, health care provider and insurance laws. The parties
shall execute one or more business associate or other agreements with respect to HIPAA compliance and certain other data governance
and security matters, in each such case in mutually agreeable form.

 

		26.	PUBLICITY.

 

Neither party shall directly
or indirectly publish, approve or issue any press release or public statement relating to the relationship of the parties to this
Agreement or any products furnished or Services performed by EVERSANA for Client (each, a “Press Release”), without
the prior written consent of the other party as to both content and timing of such Press Release, which approval may not be unreasonably
withheld, delayed or conditioned by the non-publishing party.

 

		27.	[INTENTIONALLY OMITTED].

 

 

 

		28.	INSURANCE.

 

		28.1	Insurance by Client. Client shall maintain during the Term the following insurance coverage:

 

		(i)	Commercial general liability insurance, including products liability insurance
on Client’s Products, which insurance shall be fully sufficient (in terms of coverage and policy limits) to cover property
loss or damage and bodily injury or death arising from the Products. Such insurance shall be written on an ISO occurrence form
CG 00 01 12 04 (or a substitute form providing equivalent coverage) and shall cover, among other things, bodily injury and property
damage arising from products-completed operations and liability assumed under an insured contract including Client’s contractual
liability to indemnify EVERSANA under Section 13 hereof. The limits of such insurance shall not be less than $10,000,000 per occurrence.
Such insurance shall name EVERSANA and its subsidiaries as additional insureds using ISO additional insured endorsement CG 2015
0704 or a substitute providing equivalent coverage. This insurance shall apply as primary insurance with respect to any other insurance
or self-insurance program.

		(ii)	Fire and extended property insurance sufficient to cover the replacement
value for all Products while in the possession or under the control of EVERSANA.

		(iii)	Upon request, Client shall provide EVERSANA with a Certificate of Insurance
which shall indicate all insurance coverage required by this provision herein and that EVERSANA will be provided with notice prior
to substantial modification or cancellation of such policies in accordance with policy provisions. Notwithstanding the foregoing,
Client will be responsible for providing EVERSANA with no less than thirty (30) days’ notice of any substantial change or
cancellation of Client’s insurance.

 

    			Page 12 of 23 

    	 

    

  

 

 

 

28.2       Insurance
by EVERSANA. EVERSANA shall maintain during the Term the following insurance coverage:

 

		(i)	Warehouseman’s legal liability insurance in the amount of at least
$5,000,000. Client acknowledges that such warehouseman’s legal liability insurance also insures property in the possession
of EVERSANA other than products of Client.

		(ii)	Worker’s Compensation insurance as required by law.

		(iii)	Commercial general liability insurance and umbrella insurance having a combined
limit of not less than $1,000,000 per occurrence and $10,000,000 annual aggregate. Such insurance shall be written on an ISO claims
made form CG 00 02 1204 (or a substitute for providing equivalent coverage).

		(iv)	Professional Liability and Errors and Omissions Liability insurance covering
liability for loss or damage due to an act, error or negligence having a limit of $10,000,000 annual aggregate.

 

Upon request,
EVERSANA shall provide Client with a Certificate of Insurance which shall indicate all insurance coverage required by this
provision herein and that Client will be provided with notice prior to substantial modification or cancellation of such
policies in accordance with policy provisions. Notwithstanding the foregoing, EVERSANA will be responsible for providing
Client with no less than thirty (30) days’ notice of any substantial change or cancellation of EVERSANA’s
insurance. Such insurance coverage, or the failure or inability to obtain such insurance coverage or its application, shall
not relieve, limit, or decrease a party’s responsibilities under this Agreement for any Losses including Losses in
excess of insurance limits or otherwise.

 

		29.	AUTHORITY.

 

Each party represents and
warrants to the other, as of the Effective Date, that (i) such party has the full right, power and authority to enter into this
Agreement; (ii) the execution, delivery and performance by such party of this Agreement are within its powers and have been duly
authorized by all necessary action; (iii) the execution of this Agreement by such party and the performance by such party of its
obligations and duties hereunder do not and will not violate any agreement, applicable law, judgment, injunction, order or decree
to which it is a party or by which it is otherwise bound; and (iv) when executed and delivered by it, this Agreement shall constitute
the legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms.

 

    			Page 13 of 23 

    	 

    

  

 

 

 

		30.	DEBARMENT.

 

EVERSANA represents
and warrants to the Client that it will not knowingly utilize the Services of any person in connection with this Agreement if
such person, or will immediately cease utilizing the Services of such person after obtaining knowledge that such person, (i)
has been excluded, debarred or otherwise is ineligible to participate in the Federal health care programs as defined in 42
U.S.C. 1320a-7b(f) (the “Federal health care programs”), or any form of state Medicaid program; or (ii) has been
convicted of a criminal offense related to the provision of health care items or Services but has not yet been excluded,
debarred or otherwise declared ineligible to participate in the Federal health care programs or state Medicaid programs; or
(iii) has been debarred or convicted (including a plea of nolo contendere) of a crime for which a person can be debarred
under Section 306(a) or 306(b) of the Generic Drug Enforcement Act (21 U.S.C. § 301 et seq.). EVERSANA agrees to notify
the Client in writing immediately in the event of any such debarment, exclusion, conviction, threat or indictment occurring
during the term of this Agreement. If at any time during the term of this Agreement, EVERSANA or their personnel becomes the
subject of any proceedings for disqualification, debarment, delisting, exclusion, or denial or revocation of licensure, as
described above, the Client shall have the right to terminate this Agreement effective upon the date of such notice.

 

(Signature Page Follows)

 

    			Page 14 of 23 

    	 

    

  

 

 

 

This
agreement has been entered into as of the Effective Date. 

 

	EVERSANA Life Science Services, LLC	 	
        Humanigen,
Inc. 

	 	 	 
	By: /s/ Edgar Gutierrez	 	By: /s/ Edward Jordan
	Name: Edgar Gutierrez	 	Name: Edward Jordan
	Title:  Director, Contracts	 	Title: Chief Commercial Officer
	Date:  1/9/2021	 	Date: 1/9/2021

 

    			Page 15 of 23 

    	 

    

  

 

 

 

Exhibit A

Marketing
and Market Access

 

Recitals

 

A
Master Services Agreement (“Agreement”) was entered into by and between EVERSANA and Client effective January 8, 2021.

Pursuant
to Section 1 of the Agreement, the parties now enter into this Exhibit A for the purposes of setting forth additional terms
and conditions applicable to the specific market access services to be provided by EVERSANA to Client.

 

Services

 

A.       Client
desires to have EVERSANA furnish Marketing and Market Access services (“Marketing and Market Access Services”).

B.       These
Marketing and Market Access Services are more fully described in the primary SOW executed by the Parties. The primary SOW shall
set forth a detailed description of the Marketing and Market Access Services to be provided by EVERSANA to Client and the fees
to be paid to EVERSANA by Client in connection therewith. This Exhibit B sets forth additional terms and conditions applicable
to the Parties in connection with the Market Access Services described in a SOW executed by the parties.

 

Additional
Terms and Conditions

 

1.  Client Acknowledgement.
Client understands and agrees that EVERSANA may perform similar Market Access Services for third parties using the same personnel
that EVERSANA may use for rendering Market Access Services for Client hereunder, subject to EVERSANA’s obligations respecting
Client’s Confidential Information pursuant to the Agreement.

 

2          Trade
Secrets. It is the policy of Client to respect the trade secrets of all other parties, including EVERSANA, and to comply with
all relevant state and federal laws regarding trade secrets. EVERSANA hereby warrants that, to the best of its knowledge, it does
not employ any information-gathering methods that violate state or federal laws governing trade secrets, and that it will not employ
any information- gathering methods that violate state or federal laws governing trade secrets in the performance of this Agreement.
EVERSANA further warrants that it will not, during its performance under this Agreement, seek to learn any trade secret of any
third party, and that it will not at any time disclose to Client any trade secrets belonging to any third party. EVERSANA hereby
indemnifies Client and holds Client harmless for any violations of state or federal laws regarding trade secrets arising out of
EVERSANA’s activities under this Agreement.

 

		3.	Working Arrangements

 

3.1       All
Marketing and Market Access Services shall be performed at EVERSANA’s premises or another site mutually agreed by the parties.
Client shall provide the items set forth in each SOW. Upon receipt of notice from Client that a consultant is not suitable, EVERSANA
shall remove such consultant from the performance of Market Access Services, and will provide a qualified replacement as quickly
as possible.

 

    			Page 16 of 23 

    	 

    

  

 

 

 

3.2       Client
will ensure that all Client personnel who may be necessary or appropriate for the successful performance of the Marketing and Market
Access Services will, on reasonable notice: (i) be available to assist EVERSANA personnel by answering business, technical and
operational questions and providing requested documents, guidelines and procedures in a timely manner; (ii) reasonably cooperate
in the Market Access Services as reasonably necessary for performance under a SOW; and (iii) be available to assist EVERSANA with
any other activities or tasks required to complete the Market Access Services in accordance with the SOW.

 

4.         EVERSANA
Personnel. Neither EVERSANA nor its personnel are or shall be deemed to be employees of Client. EVERSANA shall be responsible
for the compensation of its personnel, in addition to any applicable employment taxes, workmen's compensation and any other taxes,
insurance or provisions associated with the employment of personnel.

 

		5.	Fees.

 

5.1       When
EVERSANA contracts with broadcast or print media for Marketing and Market Access Services performed under this Agreement (“Media
Buys”), EVERSANA will, wherever practicable, contract on behalf of Client in a format substantially similar to that promulgated
by the American Association of Advertising Agencies (“AAAA”). EVERSANA will use commercially reasonable efforts to
guard against loss to Client through failure of media suppliers to properly execute their commitments; however, under no circumstance
shall EVERSANA be responsible for the acts or omissions of media suppliers. Media Buys will be subject to EVERSANA’s standard
mark-up, as referenced on the applicable SOW, and will be invoiced by EVERSANA upon issuance of the insertion order.

 

5.2       When
EVERSANA contracts with broadcast or print media for Marketing and Market Access Services performed under the SOW, EVERSANA will
guard against loss to Client through failure of media suppliers to properly execute their commitments. EVERSANA will secure for
Client’s account all credits and adjustments due to Client from media by reason of the publication or broadcast of any of
Client’s advertising not in accordance with the contract specifications or trade custom. In addition, EVERSANA will either
credit or pay to Client, at Client’s sole option, the proportionate share of EVERSANA’s total rebates, credits or other
adjustments which EVERSANA receives from media in a ration equal to the percentage that Client’s business bears to EVERSANA’s
total business.

 

5.3       Sales,
use and other similar taxes by a governmental authority will be reimbursed by Client in a similar manner to other expenses associated
with each Project. All pass-through costs invoiced to Client will be at actual cost with no mark-up.

 

5.4       The
initial SOW budget for a specific project will necessarily include cost estimates based upon initial concepts and preliminary estimates,
and EVERSANA will be authorized to commence work and incur expenses on that particular project based upon Client’s approval
of such preliminary SOW estimate and authorization up to an amount not to exceed [***]% of the budgeted costs so approved. EVERSANA
will submit a revised cost estimate to Client if costs for a project are anticipated to exceed the original budget by more than
[***]%, and this revised estimate must be approved by Client before work on that project continues. Once final concepts for a project
are approved and final estimates can be obtained, EVERSANA will submit a revised SOW budget for Client’s approval. Following
such approval, EVERSANA will be permitted to authorize expenditures up to [***]% of the budgeted costs so approved; provided, however,
that EVERSANA will advise Client in a timely fashion, and will obtain Client’s approval of the revised estimate, if the cost is anticipated to exceed
[***]% of the budgeted costs approved in the revised workplan budget for a project.

 

    			Page 17 of 23 

    	 

    

  

 

 

 

		6.0	Third Party Approvals

 

6.1       Each
SOW submitted to Client by EVERSANA is subject to the review and written approval of Client prior to the time EVERSANA incurs liability
to third parties in connection with the projects contained in such SOW. Furthermore, all drafts of any deliverables prepared by
EVERSANA including but not limited to, proposed journal advertisements, training materials, media copy, advertisements or other
promotional material used to promote the products (collectively, the “Promotional Material”) will be prepared by EVERSANA
using commercially reasonable efforts to ensure compliance with all applicable laws, rules and regulations, and will be submitted
to Client for review and approval prior to publication or use. Client is responsible for reviewing all deliverables (including
Promotional Material) prepared by EVERSANA and, for ensuring such deliverables comply with all applicable laws, rules and regulations.
Client will have the right to make any editorial changes it desires prior to publication or use; provided, however, that Client
must notify EVERSANA in writing of either its approval or disapproval and/or required editing of Promotional Material as promptly
as practicable, but in no event less than 48-hours prior to the planned publication or use. Client shall be responsible for all
cancellation fees.

 

6.2       EVERSANA
will be responsible for obtaining appropriate consents, authorizations and approvals from third parties for use of approved Promotional
Material in connection with the Market Access Services; provided, however, that Client will be responsible for obtaining all appropriate
consents, authorizations and approvals in connection with scientific or medical papers or scientific consultation required in connection
with the Market Access Services rendered by EVERSANA. Certain Promotional Material may contain the intellectual property of third
parties pursuant to a license or other arrangement which permits Client to use such property only in connection with a specific
project or campaign, and which would require additional payments for a different or extended use by Client. EVERSANA will notify
Client of any material conditions or limitations relating to such approvals EVERSANA has obtained as part of the approval process
for specific projects and campaigns, and Client will be solely responsible for any fees or other charges associated with its different
or extended use of intellectual property so licensed from a third party. EVERSANA makes no representations or warranties with regard
to the legal or appropriate use of Promotional Material outside of the United States; however, EVERSANA will use all reasonable
efforts to obtain such rights for Client if requested to do so.

 

 

End
of Exhibit A

 

    			Page 18 of 23 

    	 

    

 

 

 

Exhibit
B

Field Solution
Services

 

 

Recitals

 

A Master
Services Agreement (“Agreement”) was entered into by and between EVERSANA and Client effective January 8, 2021.

Pursuant
to Section 1 of the Agreement, the parties now enter into this Exhibit B for the purposes of setting forth additional terms
and conditions applicable to the specific field solution services to be provided by EVERSANA to Client.

 

Services

 

		A.	Client desires to have EVERSANA provide Field Solution services (the “Field Solution Services”).

B.  The
Field Solution Services are more fully described in the primary SOW executed by the Parties, and include the provision of Field
Sales, Market Access and Medical Affairs teams to include all supporting services. The primary SOW shall set forth a detailed description
of the Field Solution Services to be provided by EVERSANA to Client and the fees to be paid to EVERSANA by Client in connection
therewith. This Exhibit D sets forth additional terms and conditions applicable to the Parties in connection with the Field Solution
Services described in a SOW executed by the parties.

 

Additional
Terms and Conditions

 

		1.	Representations and Warranties Specific to the Field Solution Services

 

		1.1	EVERSANA represents warrants and covenants that:

 

1.1.1       EVERSANA
shall perform the Field Solution Services in a professional, workmanlike manner and in accordance with those specifications and
timelines which are agreed to in advance and in writing by EVERSANA and Client;

 

1.1.2       the
personnel assigned to perform the Field Solution Services shall be capable professionally to perform the Field Solution Services
in accordance with any agreed upon hiring profile that may be set forth in a SOW;

 

1.1.3       EVERSANA
shall remain responsible to Client for the performance or failure to perform Field Solution Services by any employee or independent
contractor engaged by EVERSANA to perform the Field Solution Services; and

 

1.1.4       EVERSANA
is not a party to any agreement which would prevent it from fulfilling its obligations under a Field Solution Services SOW and
that during the term thereof, it will not enter into any agreement to provide services which would prevent it from performing the
Field Solution Services to Client under an executed SOW.

 

    			Page 19 of 23 

    	 

    

 

 

 

 

		1.2	Client represents warrants and covenants that:

 

1.2.1       Client
will act in good faith to provide EVERSANA with the necessary materials, information, product training, and assistance
reasonably required to enable EVERSANA to perform the Field Solution Services in compliance with all applicable law. Certain
Client obligations and responsibilities unique to a specific SOW may be specified within a SOW;

 

1.2.2       Client
either owns the product(s) that is the subject of a SOW, or has received all lawful authority from a third party necessary to grant
EVERSANA the right to provide the Field Solution Services described in a SOW. Client’s patents, copyrights, trademarks, trade
names and trade dress do not infringe on any intellectual property or product rights of any third party;

 

1.2.3       Client
is responsible for reviewing and approving Client’s product promotional materials and literature and for ensuring all such
materials comply with applicable laws;

 

1.2.4       the
program(s) pursuant to which EVERSANA is performing the Field Solution Services is a Client program that is being implemented by
EVERSANA and as such, Client is responsible for ensuring that the program set forth in a SOW adheres to applicable law;

 

		1.2.5	Client is responsible for complying with all state and county drug disposal

ordinances;

 

1.2.6       Client
is responsible for all decisions concerning the marketing, planning, strategy and detailing of its Product, and shall have the
sole right and responsibility for establishing and modifying the terms and conditions of the sale of its Product, including without
limitation, terms and conditions such as the price at which the Product will be sold, whether the Product shall be subject to any
discounts, the distribution of the Product, and whether credit is to be granted or refused in connection with the sale of any Product;
and

 

1.2.7       Client
is responsible for all regulatory reporting requirements including but not limited to aggregate spend reporting, reporting required
by any State, as applicable, and pursuant to the disclosure requirements set forth in the Patient Protection and Affordable Care
Act (the “ACA”) (including but not limited to Section 6002 of the ACA, commonly referred to as the Physician Payments
Sunshine Act). EVERSANA shall cooperate with and assist Client, as reasonably requested in connection with such reporting requirements,
including by providing Client, on a monthly basis, with details of EVERSANA’s aggregate spending in connection with the Program,
to allow Client to comply with the Patient Protection and Affordable Care Act and similar reporting requirements imposed by any
state laws.

 

1.2.8       Except
as set forth in Section 4 of this Exhibit, Client is responsible for any severance payments, if any, due to any of the EVERSANA
sales representatives or other field service employees, for any sales representative that is terminated by EVERSANA as a result
of a termination request made by Client.

 

		2.	End of Term Expenses (Termination or Expiration)

 

(a)       In
addition to those expenses set forth in Section 3.5 of the Agreement, in the case of: (a) termination of the Field Solution
SOW by EVERSANA (for any reason other than as set forth in Sections 3.1 - 3.3 of the
Agreement) or by Client (for any reason other than as set forth in Section 3.2 – 3.3 of the Agreement), or (b) at the
end of the Term, Client shall promptly pay (or if paid by EVERSANA, promptly reimburse) EVERSANA for:

 

(i)       the
balance due for any un-cancellable expenses or future financial obligations directly related to the promotion of the Client’s
Product; and

 

    			Page 20 of 23 

    	 

    

 

 

 

 

(ii)       any
severance payments due any of the EVERSANA sales representatives or other field service employees, if any, terminated by EVERSANA
as a result of the termination of the Field Solution SOW.

 

(b)       In
the event EVERSANA employees were provided with use of a fleet automobile, a one-time fee per leased vehicle as a lease early termination
fee (if any) would apply; and

 

(i)       a
vehicle disposal fee in the amount equal to the net loss to EVERSANA on such fleet vehicles determined by deducting the net sale
proceeds from the remaining book value or each fleet vehicle, as of date the fleet vehicle is returned to EVERSANA’s fleet
vehicle provider (the “Vehicle Disposal Calculation”), plus costs to transport vehicle for remarketing and all costs
and auction fees to prepare the fleet vehicle for sale and remarket; and

 

(ii)     all
remaining interest obligations, management fee changes and depreciation payments due between the month the fleet vehicle lease
is terminated and the 24-month anniversary of the fleet vehicle lease;

 

(iii)    all
maintenance expenses, fuel, and fleet management service card fees incurred through the date the fleet vehicle is surrendered to
EVERSANA.

 

		3.	Conversion

 

(a)       Notwithstanding
Section 8 of the Agreement, during the Term of the Field Solution SOW, Client may solicit, employ or retain one or more EVERSANA
sales representatives performing Services hereunder (a “Conversion”) provided that: (i) such hiring may not occur prior
to the first anniversary of date the sales representative commenced provision of the Field Solution Services (the “Deployment
Date”) and (ii) Client provides at least ninety (90) days prior written notice to EVERSANA of any Conversion. In the event
Client wishes to implement a Conversion prior to the first anniversary of the applicable Deployment Date, Client shall pay EVERSANA
a fee of [***] Fees per sales representative . There shall be no Conversion fee due thereafter.

 

(b)       Client
understands and agrees that EVERSANA cannot guaranty that any sales representative will agree to participate in a Conversion.

 

(c)       In
the event Client implements a Conversion, the parties agree that any and all training materials made available to the sales representatives
will be returned to EVERSANA, it being understood and agreed that the EVERSANA proprietary training modules constitutes valuable
and proprietary information of EVERSANA and is subject to the confidentiality obligations set forth in Sections 6 and 7 of the
Agreement.

 

(d)       In
the event Client conducts a Conversion and the converted EVERSANA sales representative had been provided with use of a fleet
automobile leased, rented or owned by EVERSANA and Client wishes to commence an arrangement with the fleet vendor to assume
such cars (and all associated costs and liabilities) under Client’s name, the converted EVERSANA sales representative
may only to continue to have access to such automobile following the Conversion if Client either: (i) registers the fleet
automobile under its name; or (ii) ensures that EVERSANA remains named as an additional insured under Client’s
automobile insurance policies until such time as the vehicle is registered in Client’s name (which shall occur no later
than three (3) months following the Conversion). The Parties understand and agree that it is solely Client’s obligation
to ensure one of the above actions are taken and Client shall be responsible for indemnifying, defending and holding EVERSANA
harmless for all damages resulting from Client’s failure to take such action. The Parties further agree that on the
effective date of the Conversion, Client shall destroy the EVERSANA insurance card(s) in the fleet vehicle(s) of the
converted EVERSANA sales representatives.

 

    			Page 21 of 23 

    	 

    

 

 

 

(e)       In
the case of a Conversion, Client shall have full rights to directly engage with any consultant, independent contractor, or third-party
in its sole discretion without limitation.

 

		4.	Performance of the Field Solution Services

 

If
Client independently observes, learns or hears that the performance of any sales representative is unsatisfactory or is not in
compliance with the provisions of the Agreement, the Field Solution Services SOW or applicable law, Client shall notify EVERSANA
in writing. EVERSANA shall promptly address the performance or conduct of such person in accordance with its internal human resource
policies. In the event that Client determines in good faith that a sales representative has violated any applicable law, regulation
or policy including applicable laws, Client shall also notify EVERSANA in writing. EVERSANA shall promptly address the issue and
take all reasonable and appropriate action (including but not limited to termination of such employee), and Client shall have no
responsibility for any costs or actions so taken (including but not limited to any obligation to pay severance or other expenses
associated with the termination of such employee). No such action shall be contrary to EVERSANA’s internal human resource
policies and procedures. It is further agreed that each sales representative’s continued employment shall be contingent upon
satisfaction of certain performance criteria established periodically by the Parties, and Client shall have no responsibility for
any costs or actions taken (including but not limited to any obligation to pay severance or other expenses associated with the
termination of such employee) in response to a sales representative’s failure to achieve the requisite level of performance
so established.

 

		5.	Independent Contractors; EVERSANA Personnel

 

Supplementing Section 12 (Independent Contractors)
of the Agreement, the parties agree as follows:

 

5.1       EVERSANA
and its directors, officers, employees and any persons providing services under the Agreement and any SOW are at all times independent
contractors with respect to Client. Persons provided by EVERSANA to perform Field Solution Services shall not be deemed employees
of Client. Neither this Agreement nor the Field Solution Services to be rendered hereunder shall for any purpose whatsoever or
in any way or manner create any employer-employee relationship between EVERSANA, its directors, officers, employees and any persons
providing Field Solution Services under the Agreement and Client. Client understands that EVERSANA may utilize independent contractors
in connection with its performance of the Field Solution Services.

 

5.2       EVERSANA
is, and at all times shall remain, solely responsible for the human resource and performance management functions of all EVERSANA
personnel provided to perform the Field Solution Services. EVERSANA shall be solely responsible for all disciplinary, probationary
and termination actions taken by it, and for the formulation, content and dissemination of all employment policies and rules (including
written disciplinary, probationary and termination policies) applicable to its employees, agents and contractors (individually,
an “EVERSANA Employee” and collectively, the “EVERSANA Employees”).

 

    			Page 22 of 23 

    	 

    

 

 

 

5.3       EVERSANA
shall obtain and maintain worker’s compensation insurance and other insurances required for EVERSANA Employees performing
the Field Solution Services and acknowledges that Client does not, and shall not obtain or maintain such insurances, all of which
shall be EVERSANA’s sole responsibility.

 

5.4       EVERSANA
acknowledges and agrees that EVERSANA Employees are not, and are not intended to be or be treated as, employees of Client and that
no such individual is, or is intended to be, eligible to participate in any benefits programs or in any Client “employee
benefit plans” (as defined in Section 3(3) of ERISA) (“Client’s Benefits Plan”).

 

5.5       Except
as otherwise set out in this Agreement or in a SOW, Client shall have no responsibility to EVERSANA or any EVERSANA Employee for
any compensation, expense reimbursements or benefits (including, without limitation, vacation and holiday remuneration, healthcare
coverage or insurance, life insurance, pension or profit-sharing benefits and disability benefits), payroll-related or withholding
taxes, or any governmental charges or benefits (including, without limitation, unemployment and disability insurance contributions
or benefits and workers compensation contributions or benefits) that may be imposed upon or be related to the performance by EVERSANA
or its employees, agents or contractors of the obligations under this Agreement or any SOW, all of which shall be the sole responsibility
of EVERSANA. To clarify, Client will not withhold any income tax or payroll tax of any kind on behalf of EVERSANA.

 

5.6       Limitations.
Notwithstanding anything to the contrary in this Section 5, EVERSANA shall have no obligation or responsibility for any damages,
liability, loss and costs, including but not limited to attorney’s fees (collectively, “Liability”) to the extent
such Liability is attributed to either. discriminatory and/or intentional acts of Client, its employees, agents or contractors.

 

		6.	Training Obligations of the Parties

 

The training responsibilities of the parties are
as follows:

 

(a)       EVERSANA
shall train all EVERSANA sales representatives concerning: selling skills, compliance with applicable laws, use of sales force
automation software, expense management policies, EVERSANA human resource policies, procedures and administration and other applicable
EVERSANA internal human resource and general compliance policies and procedures, and recruiting/onboarding. Client shall have the
opportunity to review all training materials used by EVERSANA in advance of such training and may require revisions as deemed appropriate
by the Client. Client may assist EVERSANA personnel in such training.

 

(b)       Client
shall provide all training content and sales and training objectives, including but not limited to, clinical studies, regulatory
documents, Product-specific information including Product complaint-handling procedures, applicable specific Client health care
compliance policies and Client customer service policies and procedures, orientation to Clients’ businesses, and adverse
event reporting policies and procedures to EVERSANA (the “Training Material”). EVERSANA shall train all EVERSANA sales
representatives in accordance with the sales and training objectives provided by Client and described in the Training Materials.
The parties agree to work together to mutually determine if, when, and at what cost additional training shall be provided.

 

 

Page 23 of 23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]